Biotechnology M&A » By The Online Investor Staff, updated Sun., Apr. 18, 3:59 AM
Recent mergers and acquisitions in the Biotechnology M&A category.
| This Slide: #11 of 83 |
Slide #11. Retrophin — Manchester Pharmaceuticals
Acquirer:
Retrophin (RTRX)
Acquiree:
Manchester Pharmaceuticals
Details:
Retrophin, Inc. (NASDAQ:RTRX) today announced the completion of the previously announced acquisition of Manchester Pharmaceuticals LLC for a total of $62.5 million, including an upfront payment of $29.5 million, plus other payments based on product sales.
Retrophin is a biopharmaceutical company focused on identifying, developing and delivering therapies to people living with rare diseases. Co.'s commercialized products include Chenodal (chenodiol tablets) for the treatment of radiolucent stones in well-opacifying gallbladders in patients; Cholbam (cholic acid capsules), a treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC (tiopronin), a treatment for cystinuria, a genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Open the RTRX Page at The Online Investor »
|
|||||||||
Open the RTRX Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
 
|
Strong Buy (3.75 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: RTRX Stock Forecast Based on Zacks ABR data; powered by Xignite |
